Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial

Autor:	Min Qi, Min Tan, Yan Huang, Hai-Fu Li, Jun Chen, Xiao-Ting Zhao, Li-Yuan Long, Xingwang Hu, Xue-Gong Fan, Ruochan Chen, Ze-Bing Huang, Cheng-Jin Liao
Rok vydání:	2021
Předmět:	Microbiology (medical) HBsAg medicine.medical_specialty Chronic hepatitis B Gastroenterology law.invention Randomized controlled trial Antigen law Internal medicine medicine Clinical endpoint Seroconversion Nucleoside (acid) analogues Original Research Add-on therapy Nucleoside analogue business.industry virus diseases digestive system diseases PegIFNα-2b Infectious Diseases HBeAg Peginterferon alfa-2b business medicine.drug
Zdroj:	Infectious Diseases and Therapy
ISSN:	2193-6382 2193-8229
DOI:	10.1007/s40121-021-00497-5
Popis:	Introduction Hepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). However, its rate is extremely low with nucleoside (acid) analogues (NAs) monotherapy. Peginterferon could enhance HBsAg clearance. This study aimed to evaluate the efficacy of peginterferon alfa-2b (PegIFNα-2b) in NAs-experienced patients with CHB with negative HBeAg and low HBsAg level. Methods HBeAg-negative patients with CHB who had received NAs therapy over 24 weeks with HBsAg
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d68c979646cbfae642af311378226432 https://doi.org/10.1007/s40121-021-00497-5 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.